Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status approved
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 63629-5688; 49452-7523; 59116-0631; 0093-3234; 70518-0185; 51552-1044; 51927-0081; 50090-2013; 59762-5000; 62135-960; 70518-1829; 70518-3732; 0013-0102; 71610-577; 62705-0222; 62991-2704; 59762-0104; 70518-2342; 71610-706; 49964-0018; 57294-021; 50090-0086; 51927-0054; 59116-0632; 0591-0796; 23155-019; 0013-0101; 63629-9715; 38779-0176; 59116-0630; 59116-0633; 68022-7065
UNII 3XC8GUZ6CB
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Enterocolitis07.08.03.0030.000303%
Eosinophilia01.02.04.0010.001818%
Eosinophilic myocarditis02.04.03.002; 01.02.04.0070.000455%Not Available
Eosinophilic pneumonia22.01.01.004; 01.02.04.0030.001515%Not Available
Erythema23.03.06.0010.002728%Not Available
Erythema multiforme10.01.03.015; 23.03.01.003--
Eye disorder06.08.03.001--Not Available
Eye inflammation06.04.05.002--Not Available
Eye pain06.08.03.002--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.001212%
Facial paralysis17.04.03.0080.000303%Not Available
Factor II deficiency03.15.01.004; 01.01.01.007--Not Available
Faeces discoloured07.01.03.0020.000818%Not Available
Febrile neutropenia08.05.02.004; 01.02.03.0020.001667%
Feeling jittery08.01.09.0160.001182%Not Available
Fistula15.03.02.001--Not Available
Folate deficiency14.12.02.006--Not Available
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.002--
Gamma-glutamyltransferase increased13.03.04.024--
Gastric ulcer07.04.03.0020.000303%
Gastrooesophageal reflux disease07.02.02.0030.001788%
Gastrointestinal disorder07.11.01.0010.017912%Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.0040.000303%
Glomerulonephritis20.05.01.001; 10.02.01.0060.000455%Not Available
Glomerulonephritis rapidly progressive10.04.04.008; 20.05.01.0040.000303%Not Available
Glossodynia07.14.02.0010.000818%Not Available
Goitre14.11.01.008; 05.02.01.001--Not Available
Gout15.01.06.001; 14.09.01.001--Not Available
Granulocytopenia01.02.03.0030.000455%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene